Tag Archives: business

LSN Fundraising Bootcamp at London Bio-Innovation Week 2025 

12 Nov

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wp

Refine your fundraising strategy and investor engagement with hands-on insights from industry experts.

Life Science Nation (LSN) invites early-stage life science and healthcare executives to an exclusive Fundraising Bootcamp during London Bio-Innovation Week 2026. This free, half-day workshop is designed to help entrepreneurs strengthen their fundraising strategy, improve investor engagement, and sharpen their pitching skills through interactive, expert-led sessions.

Date and Time: Tuesday, December 2, 1:00 PM – 5:00 PM
Location: Fieldfisher Law Firm, Riverbank House, 2 Swan Lane, London
Cost: Free

The LSN Fundraising Bootcamp brings together investors, fundraising professionals, and industry experts to provide a clear view of the current investor landscape and actionable strategies for early-stage companies preparing for their next raise.

Session topics include It All Starts with The Story, Global Partnering Campaign – Investor Landscape, GTL & GPC, LSN Event Partnering Process, and Maximizing The Power Of Your Pitch. The program concludes with a live Sharktank-style session where participants pitch their companies to a panel of experts and receive real-time feedback.

This interactive event offers practical guidance and the chance to connect with key players in the global life science ecosystem.

To register, please complete the contact form:

Sign Up Fundraising Bootcamp Register for RESI London

Tags: , , , , ,

Hot Investor Mandate: Early-Stage Focused VC Firm Invests in Pre-Seed to Series A Healthcare Companies With AI-Driven Technologies

12 Nov

This venture capital firm with offices in the US is exclusively focused on the AI transformation of healthcare, operating through a physician-centric model that leverages a broad network of medical professionals actively involved in both the investment process and the development of AI solutions, particularly in medical imaging. 

The firm invests at the pre-Seed, Seed, and Series A stages, with typical check sizes ranging from $1 million to $2 million. While most investments have been made in U.S.-based companies, the firm remains open to international opportunities, including those in Europe and Asia. 

Investment focus is tightly concentrated on disruptive AI-driven technologies in the medical imaging market. The firm does not invest in traditional therapeutics or medical devices, and is currently not considering opportunities outside of AI-centric digital health technologies related to imaging. It is open to investing in companies as early as the pre-prototype stage, provided they are aligned with the firm’s strategic thesis. 

The firm seeks to partner with highly driven management teams who possess deep domain expertise across imaging, artificial intelligence, and medical software. While the firm typically co-invests, it maintains an active, hands-on approach, especially through the support of its physician investor network, which helps accelerate product development and clinical relevance. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Family Office-Backed Life Sciences Fund Invests Across Therapeutics, Diagnostics, and Digital Health Globally

12 Nov

This life sciences-focused investment firm backed by a prominent family office is actively investing in life science and healthcare companies across the globe, with a focus on those that are based near their headquarters. 

The firm invests in early-stage healthcare companies, with interest in therapeutics, diagnostics, and digital health. It is agnostic to technology type and therapeutic indication, but prefers opportunities with robust pre-clinical data. The firm is open to both pre-clinical and clinical-stage projects, though it does not invest in medical device companies at this time. 

The firm is focused on supporting innovative technologies and is open to partnering with both first-time and experienced founding teams. It is flexible in its role, willing to act as either a lead investor or a co-investor, depending on the structure and needs of the financing round.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Evergreen Fund Actively Seeking Therapeutics and Medical Device Opportunities, Investing Up to $10M in the US and Beyond

12 Nov

This corporate strategic evergreen fund based in the US has invested in over 50 life sciences companies and considers both public and private opportunities in the United States and internationally. The firm is a flexible investor, with initial allocations typically ranging from $1 million to $10 million, depending on the developmental stage of the company. 

The firm invests in therapeutics and medical devices, with the latter limited to implantable products requiring PMA submission. It invests exclusively in companies with clinical-stage assets, and is indication-agnostic, open to innovation across all areas of medicine. 

This investor adopts a flexible approach to management teams, and is willing to take a more hands-on role in cases where founding teams have limited internal resources. A high level of transparency is required from portfolio companies, and the firm actively supports strategic planning around value-driving clinical studies that can meaningfully advance the company’s trajectory. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Europe-Based VC Invests Across All Life Science Sectors, With A Focus on Those Based in US and Europe

12 Nov

A Europe-based venture capital firm invests across two primary verticals: healthcare innovation and sustainability. The firm typically invests at the seed stage, with initial check sizes ranging from €1 million to €5 million. Its geographic deployment is relatively balanced, with approximately half of investments made in Europe and the other half in the United States. The firm shows particular interest in U.S.-based companies founded by European entrepreneurs. 

The firm invests across therapeutics, diagnostics, medical devices, and digital health, taking an agnostic approach within these sectors. It does not enforce strict criteria regarding the composition or background of founding teams. 

Open to both leading and co-investing, the firm places strong emphasis on the mission and purpose behind each company, placing value on teams with a compelling “why” that drives their approach to solving pressing problems in healthcare. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

The Real “Secret Sauce” for Startup Success 

4 Nov

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wp

Many entrepreneurs hope there’s a “secret sauce” or formula for success. In reality, it’s much more about attitude and persistence than any secret trick. Across hundreds of startups we’ve met, the most consistent trait among successful founders is determination — the willingness to try every avenue, face setbacks head-on, and keep finding new ways forward. 

One of the toughest challenges founders face is getting in front of investors. Whether it’s outreach for a partnering event, sending a cold email, or following up after a meeting, responses can be few and far between. This silence often feels discouraging — some see it as rejection or assume something’s wrong with their company. More often than not, though, it’s simply a matter of timing, clarity, or persistence. 

At RESI, we’ve seen time and again that the entrepreneurs who keep going — who adapt and stay visible — are the ones who eventually break through. Here are a few strategies that can make the difference: 

  1. Keep Following Up

Persistence pays off. One CEO sent 20 follow-up emails over six months before finally securing a meeting. The investor only vaguely remembered the company but appreciated the founder’s consistency and determination. The lesson? As long as you haven’t heard “no,” keep reaching out. You’re not being a nuisance — you’re demonstrating commitment. 

  1. Find Another Approach

When one CEO didn’t get as many meetings as hoped at a RESI event, he asked which investors from his target list had checked in. Armed with that information, he sought them out while networking, leading to several meaningful conversations. Whether it’s catching investors after a panel, reaching out via LinkedIn, or changing your communication style, adapt until you make contact. 

Register for RESI London Register for RESI JPM
  1. Maximize Every Opportunity

Visibility matters. One Innovator’s Pitch Challenge (IPC) participant hosted a raffle at their poster to attract attendees. The result? Buzz around their company, new ad hoc meetings, and ultimately, an IPC win. By creating a memorable experience, they stood out in a crowded environment — and investors took notice. 

Appy to Pitch at RESI London Appy to Pitch at RESI JPM

Takeaway 

There’s no shortcut to building investor relationships — but determination, creativity, and consistent action go a long way. Keep putting yourself and your company out there, follow up with intention, and make every opportunity count. At RESI, we see it time and again: the founders who stay proactive and visible are the ones who get results. 

Tags: , , , ,

RESI JPM 2026: A Global Hub for Life Science Connections 

4 Nov

By Matt Stanton, VP Sales US West, Central and South America, LSN

The Redefining Every Stage of Investment (RESI) Conference returns to San Francisco for RESI JPM 2026, taking place January 12–13 at the San Francisco Marriott Marquis. This two-day in-person event will be followed by three days of online partnering on January 14, 19, and 20, providing multiple opportunities to connect with investors, strategic partners, and early-stage innovators across biotech, medtech, diagnostics, and digital health.

RESI JPM is one of the the biggest and well attended investor partnering events held concurrently alongside JP Morgan Healthcare Week , RESI JPM serves as an high-impact venue for early-stage companies to meet investors and strategic partners in a focused, partnering-driven environment. Previous RESI JPM conferences have drawn more than a thousand participants, including over 700 early-stage life science investors, innovators, and industry leaders.

This year, RESI JPM 2026 welcomes companies and delegations representing more than 36 countries, reflecting the truly global reach of the RESI community. The event brings together entrepreneurs and investors from every major life science hub, creating a dynamic platform for cross-border collaboration and innovation.

We’re honored to host international cohorts from: 

  • Brisbane Economic Development Agency (BEDA) – Government Organization, Australia
  • Kobe Biomedical Innovation Cluster (KBIC) – Incubator/Accelerator, Japan
  • Monash University – Tech Hub, Australia
  • Ontario (Canada)
  • Enterprise Singapore
  • Ganesha Lab – Latin America
  • Apex Brasil
  • One Nucleus (UK)
  • O2h (UK)

These groups join a growing network of innovators supported by Life Science Nation’s (LSN) global ecosystem. LSN and the RESI Conference Series have built connections spanning every continent, linking life science startups with investors ranging from seed-stage venture funds to corporate pharma and strategic partners. The international participation seen at RESI JPM underscores LSN’s mission to connect early-stage technologies with capital and expertise across borders.

We are also grateful for the ongoing collaboration of our global partners, including Freemind, Biocat, BioPartner UK, Life Science British Columbia, Arizona Bio, Biotech Gate, MaRS Discovery District, MassChallenge, and Eurasanté — and many more.

Join us in San Francisco and online for RESI JPM 2026 to engage with the global life science community and accelerate your innovation journey. There is still time to apply to pitch in the Innovator’s Pitch Challenge, where startups gain exposure to investors and industry experts providing valuable feedback and connections.

To date, 90 companies have reported raising $1.29 billion from connections that began at RESI — your next breakthrough could be just one conversation away.

Register for RESI JPM Appy to Pitch at RESI JPM

Tags: , , , ,

← Older Entries
Newer Entries →